Answers are grounded in this paper and cite their sources.
Bacterial vaginosis (BV) is a common manifestation of vaginal dysbiosis, and recurrence after antimicrobial therapy remains frequent. This narrative review examines the rationale for restoring vaginal lactobacilli and evaluates oral and intravaginal interventions using selected clinical trials, evidence syntheses, and practice guidance. In a phase 2b trial, intravaginal Lactobacillus crispatus CTV-05 following metronidazole reduced 12-week recurrence from 45% to 30%. Trials of oral Lacticaseibacillus rhamnosus GR-1 plus Limosilactobacillus reuteri RC-14 reported inconsistent short-term cure outcomes. Meta-analyses suggest a reduction in BV recurrence with some preparations, with uncertainty arising from differences in strains, formulations, timing, and outcome definitions. Small trials of vaginal prebiotic gels report improvements in microbiological measures, while evidence for durable benefit remains limited. Available data provide insufficient support for extrapolating BV findings to vulvovaginal candidiasis, human papillomavirus clearance, or shiitake-derived adjuncts. The clearest evidence concerns specific interventions tested after standard BV treatment. Future trials should measure symptomatic recurrence alongside strain persistence and assess whether protection persists after dosing ends.
No takes yet. Share an insight, caveat, or question.
Paria Jafari (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: